# Clinical Cases: Global Public Health

## Case 1: Cholera Outbreak Management

### Patient Presentation
**Demographics:** 28-year-old female displaced person in a refugee camp, Eastern Democratic Republic of Congo

**Chief Complaint:** "Severe watery diarrhea and vomiting since yesterday morning."

**History of Present Illness:**
The patient is brought to the cholera treatment center (CTC) by her husband after approximately 18 hours of profuse watery diarrhea and vomiting. She reports sudden onset of painless, voluminous watery stools described as "rice water" in appearance, with an estimated 15-20 episodes since onset. Vomiting began approximately 4 hours after diarrhea onset and has been persistent, preventing oral rehydration.

She reports severe thirst, dizziness, muscle cramps in her calves and forearms, and progressive weakness. She has been unable to urinate for the past 8 hours. She lives in a section of the camp that received a new water supply point 2 weeks ago. Several neighbors in her block have presented with similar symptoms over the past 5 days; the camp health coordinator reports 47 suspected cases and 3 deaths in the past week.

The camp houses approximately 28,000 internally displaced persons with inadequate sanitation infrastructure: one latrine per 85 people (minimum standard is 1:20), intermittent water supply averaging 8 liters per person per day (minimum standard 15 L/p/d), and no systematic water chlorination at the new distribution point.

**Past Medical History:**
- No significant medical history
- Last menstrual period: 3 weeks ago (not pregnant)
- HIV status: Unknown
- Vaccination: No oral cholera vaccine

**Medications:**
- None

**Social History:**
- Displaced from her village 6 months ago due to armed conflict
- Lives in emergency shelter with husband and 3 children (ages 2, 5, and 7)
- Sources water from the new distribution point (untreated)
- Shares a latrine with 12 other families
- Malnourished diet consisting mainly of WFP rations

**Family History:**
- 5-year-old child developed diarrhea this morning

### Physical Examination
- **Vital Signs:** BP 72/40 mmHg (severe hypotension), HR 128 bpm (tachycardia), RR 28 (Kussmaul breathing), Temp 35.8°C (hypothermia), SpO2 94% on RA
- **General:** Severely ill, lethargic but responsive to voice, markedly dehydrated
- **Dehydration assessment (WHO):** Lethargic, sunken eyes, very slow skin turgor (pinch retracts > 2 seconds), unable to drink (vomiting), absent tears — **SEVERE DEHYDRATION**
- **HEENT:** Profoundly sunken eyes, dry cracked lips, dry oral mucosa with absent saliva, hoarse voice
- **Cardiovascular:** Tachycardic, weak thready pulse, cool peripheries, capillary refill 5 seconds
- **Abdomen:** Soft, diffusely tender, hyperactive gurgling bowel sounds, no rigidity
- **Extremities:** Washerwoman hands and feet (shriveled skin), painful muscle cramping in calves bilaterally
- **Neurological:** Lethargic but oriented, muscle cramps with spasms

### Workup and Results

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| Rapid diagnostic test (Crystal VC) | Positive for V. cholerae O1 | Negative |
| Stool culture (pending) | - | No growth |
| Serum sodium | 128 mEq/L | 136-145 mEq/L |
| Serum potassium | 2.4 mEq/L | 3.5-5.0 mEq/L |
| Serum bicarbonate | 8 mEq/L | 22-28 mEq/L |
| BUN | 68 mg/dL | 7-20 mg/dL |
| Creatinine | 3.8 mg/dL | 0.6-1.2 mg/dL |
| Blood glucose | 48 mg/dL | 70-100 mg/dL |
| Arterial pH | 7.12 | 7.35-7.45 |
| Hemoglobin | 14.8 g/dL | 12-16 g/dL (hemoconcentrated) |
| WBC | 12,400/uL | 4,500-11,000/uL |

**Imaging/Additional Studies:**
- Estimated fluid deficit: 10% body weight (approximately 5.5 liters for a 55 kg patient)
- Stool culture (result at 48 hours): Vibrio cholerae O1, serotype Ogawa, biotype El Tor
- Antibiotic sensitivity: Sensitive to azithromycin and doxycycline, resistant to tetracycline and co-trimoxazole
- Environmental investigation: Water samples from the new distribution point positive for fecal coliforms (> 100 CFU/100 mL) and V. cholerae detected; chlorine residual 0 mg/L (standard > 0.2 mg/L at point of use)

### Clinical Image

![Cholera outbreak response framework](case_01_image.jpg)

*Diagram illustrating the pillars of cholera outbreak response: case management (rehydration and antibiotic therapy), water-sanitation-hygiene (WASH) interventions, surveillance and laboratory confirmation, oral cholera vaccination, and community engagement. Shows the fecal-oral transmission pathway and environmental intervention points. Source: Educational illustration.*

### Diagnosis
**Acute Cholera (Vibrio cholerae O1 Ogawa, El Tor biotype) with Severe Dehydration, Hypovolemic Shock, Severe Metabolic Acidosis, Hypokalemia, Acute Kidney Injury, and Hypoglycemia, in the Context of a Camp-Based Cholera Outbreak**

**Key Diagnostic Criteria:**
- Clinical presentation: acute profuse watery "rice water" diarrhea with rapid severe dehydration consistent with cholera
- Positive rapid diagnostic test (Crystal VC) for V. cholerae O1
- Culture confirmation of V. cholerae O1 Ogawa, El Tor
- WHO severe dehydration criteria met (lethargy, sunken eyes, very slow skin turgor, unable to drink)
- Epidemiological context: outbreak setting in displaced population camp with identified contaminated water source

### Treatment Plan
1. **Immediate resuscitation (WHO Plan C for severe dehydration):**
   - IV Ringer's Lactate 100 mL/kg over 3 hours for adults: 30 mL/kg in first 30 minutes (rapid bolus), then 70 mL/kg over next 2.5 hours
   - Total initial IV volume target: approximately 5.5 liters (10% body weight)
   - Reassess dehydration status every 15-30 minutes; if still severely dehydrated after 3 hours, repeat IV bolus
   - Monitor urine output (target > 0.5 mL/kg/hr)
   - IV dextrose 50 mL of 50% dextrose for hypoglycemia
2. **Ongoing fluid replacement:**
   - Replace ongoing stool losses: measure stool output and replace volume-for-volume with ORS once patient can drink
   - ORS (reduced osmolarity WHO formula) as soon as patient can tolerate oral intake
   - Target: match ongoing losses plus maintenance fluids
3. **Electrolyte correction:**
   - Potassium replacement: IV KCl 40 mEq in first liter of maintenance fluid (do not exceed 10 mEq/hr), transition to oral KCl or potassium-rich foods when tolerating oral intake
   - Ringer's Lactate provides some bicarbonate correction (lactate metabolized to bicarbonate); monitor pH and bicarbonate with serial ABGs
4. **Antibiotic therapy:**
   - Azithromycin 1 g single dose orally (once tolerating oral intake) — reduces stool volume by 50%, shortens illness duration by 1-2 days, reduces bacterial shedding; chosen based on local resistance pattern (tetracycline-resistant strain)
5. **Nutrition:** Resume feeding as soon as patient can tolerate oral intake; breastfeeding mothers should continue breastfeeding
6. **Contact management:** Evaluate and prophylactically treat 5-year-old child with diarrhea; give household ORS packets and chlorine tablets; hygiene education on handwashing

**OUTBREAK RESPONSE (Public Health Interventions):**
7. **Immediate WASH interventions:**
   - Emergency chlorination of the implicated water distribution point (target free chlorine residual > 0.5 mg/L at source, > 0.2 mg/L at point of use)
   - Distribution of household water treatment supplies (chlorine tablets, Aquatabs) to all affected blocks
   - Emergency latrine construction to achieve minimum standard of 1:20 ratio
   - Handwashing station installation at latrines and feeding centers
8. **Surveillance and case management:**
   - Establish cholera treatment center (CTC) and oral rehydration points (ORPs) according to WHO guidelines
   - Active case finding: house-to-house surveillance in affected blocks
   - Line listing of all suspected cases with mapping for spatial analysis
   - Case fatality rate monitoring (target < 1% with adequate treatment)
9. **Vaccination campaign:**
   - Request oral cholera vaccine (OCV, Shanchol) from the WHO Global OCV Stockpile through ICG mechanism
   - Target: single-dose reactive campaign for all residents > 1 year (28,000 doses)
   - Single-dose OCV provides 40-80% short-term protection during outbreaks
10. **Community engagement:**
    - Community health workers for household education on water treatment, hygiene, and early ORS initiation
    - Address cultural beliefs about diarrhea causation and treatment-seeking behavior
    - Establish community-based surveillance and reporting

### Key Learning Points
- Cholera can cause death from dehydration within 12-24 hours if untreated; aggressive IV fluid resuscitation with Ringer's Lactate following WHO Plan C is the cornerstone of management, with a case fatality rate dropping from 25-50% (untreated) to < 1% with appropriate rehydration
- Hypokalemia is the most dangerous electrolyte disturbance in cholera (not hyponatremia) because severe hypokalemia causes cardiac arrhythmias and ileus; potassium must be aggressively replaced alongside volume resuscitation
- Outbreak response requires simultaneous clinical management AND public health interventions (WASH, surveillance, vaccination, community engagement); treating individual patients without addressing the contaminated water source will not control the outbreak
- Oral cholera vaccine from the global stockpile can be deployed reactively during outbreaks; even a single dose provides meaningful short-term protection and is a critical complement to WASH interventions
- Antibiotic resistance patterns vary geographically and temporally in V. cholerae; local susceptibility data should guide antibiotic selection, and azithromycin has emerged as a reliable first-line agent in many settings where tetracycline resistance is prevalent

---

## Case 2: Tuberculosis Control in Resource-Limited Setting

### Patient Presentation
**Demographics:** 34-year-old male mineworker, Lesotho

**Chief Complaint:** "Cough for three months with blood in the sputum and weight loss."

**History of Present Illness:**
The patient presents to the district hospital outpatient department with a 3-month history of productive cough, initially mucoid but now with intermittent hemoptysis (blood-streaked sputum, approximately 2-3 tablespoons per day for the past 2 weeks). He reports progressive weight loss of approximately 10 kg over 3 months, drenching night sweats requiring sheet changes, low-grade fevers, and decreased appetite.

He works as a gold mineworker in South Africa and returns to Lesotho periodically. His work involves underground drilling with significant silica dust exposure over 8 years. He reports that two coworkers from his shift have been diagnosed with tuberculosis in the past year. He was tested for TB 6 months ago at the mine clinic (sputum smear negative) and was told he was fine.

He lives in a small two-room house with his wife, three children (ages 4, 8, 11), his mother (age 62), and his brother. The house has poor ventilation with only one small window per room. He was diagnosed with HIV 3 years ago during routine mine health screening but has been poorly adherent to antiretroviral therapy (ART), taking his medications intermittently.

**Past Medical History:**
- HIV infection (diagnosed 3 years ago)
- Silicosis (early stage, diagnosed at mine health screening)
- Previous TB treatment 5 years ago (completed 6-month course, declared cured)
- Intermittent ART adherence

**Medications:**
- Tenofovir/lamivudine/dolutegravir (TLD) fixed-dose combination — intermittent adherence
- Co-trimoxazole 960 mg daily — not taking consistently

**Social History:**
- Gold mineworker for 8 years (silica exposure)
- Alcohol: Heavy use (traditional beer and spirits, estimated 30+ units/week)
- Smoking: 10 cigarettes/day for 12 years
- Lives in overcrowded, poorly ventilated home
- Low income, household food insecurity
- Cross-border migrant worker (Lesotho-South Africa)

**Family History:**
- Father: Died of "chest disease" at age 48 (likely TB, unconfirmed)
- Mother: Cough for 1 month (not yet evaluated)

### Physical Examination
- **Vital Signs:** BP 100/64 mmHg, HR 104 bpm, RR 22, Temp 38.4°C, SpO2 92% RA, BMI 17.2 (underweight)
- **General:** Cachectic male, chronically ill-appearing, temporal wasting, oral thrush
- **HEENT:** Oral candidiasis (white plaques on palate and tongue), poor dentition, no lymphadenopathy
- **Respiratory:** Decreased breath sounds right upper lobe, bronchial breathing right apex, coarse crackles bilaterally (right > left), dullness to percussion right upper zone
- **Cardiovascular:** Tachycardic, regular, no murmurs
- **Abdomen:** Scaphoid, mildly tender in right upper quadrant, liver palpable 3 cm below costal margin, no splenomegaly
- **Extremities:** Finger clubbing bilaterally, no edema
- **Skin:** Generalized pallor, no Kaposi lesions
- **Lymph nodes:** Bilateral axillary lymphadenopathy (< 2 cm, firm, mobile)

### Workup and Results

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| Xpert MTB/RIF Ultra (sputum) | MTB Detected, HIGH; Rifampicin resistance DETECTED | MTB not detected |
| Sputum smear (ZN stain) | AFB 3+ | Negative |
| Sputum culture (MGIT, week 3 result) | M. tuberculosis complex | No growth |
| Line probe assay (GenoType MTBDRplus) | Rifampicin resistant (rpoB mutation S531L), Isoniazid resistant (katG mutation) | Sensitive |
| Second-line LPA (MTBDRsl) | Fluoroquinolone sensitive, aminoglycoside sensitive | Sensitive |
| CD4 count | 89 cells/uL | 500-1500 cells/uL |
| HIV viral load | 128,000 copies/mL | < 50 copies/mL (suppressed) |
| Hemoglobin | 9.2 g/dL | 13.5-17.5 g/dL |
| WBC | 3,200/uL | 4,500-11,000/uL |
| Albumin | 2.4 g/dL | 3.5-5.0 g/dL |
| ALT | 62 U/L | < 41 U/L |
| Creatinine | 0.9 mg/dL | 0.7-1.3 mg/dL |
| HBsAg | Negative | Negative |
| Hepatitis C antibody | Negative | Negative |
| Urine LAM (TB-LAM) | Positive (Grade 3) | Negative |

**Imaging/Additional Studies:**
- Chest X-ray: Right upper lobe cavity (3.5 cm), bilateral upper lobe infiltrates with fibrotic changes, right hilar lymphadenopathy, volume loss right upper lobe; additionally, fine nodular pattern in bilateral lower zones consistent with silicosis
- Audiometry: Normal baseline (pre-aminoglycoside if needed)
- ECG: Sinus tachycardia, normal QTc (412 ms)
- Visual acuity: 20/20 bilaterally (baseline before ethambutol)

### Clinical Image

![MDR-TB treatment and public health response](case_02_image.jpg)

*Diagram showing the integrated approach to multidrug-resistant TB management in a resource-limited setting: drug susceptibility-guided regimen selection, HIV co-management, infection prevention and control measures, contact tracing strategy, and the social determinants of TB (mining, migration, poverty, overcrowding). Source: Educational illustration.*

### Diagnosis
**Multidrug-Resistant Pulmonary Tuberculosis (MDR-TB: Rifampicin + Isoniazid Resistant) with Cavitary Disease, HIV Co-infection with Virological Failure (Advanced Immunosuppression, CD4 89), Occupational Silicosis, and Malnutrition**

**Key Diagnostic Criteria:**
- Xpert MTB/RIF Ultra: MTB detected with rifampicin resistance
- Line probe assay confirming dual resistance to rifampicin (rpoB S531L) and isoniazid (katG) = MDR-TB by definition
- Fluoroquinolone and aminoglycoside sensitive on second-line LPA (not pre-XDR or XDR)
- High bacillary load (smear 3+, Xpert "HIGH") with cavitary disease indicating high infectiousness
- HIV co-infection with advanced immunosuppression (CD4 89) and virological failure on first-line ART
- Positive urine TB-LAM indicating disseminated TB risk in severely immunocompromised patient
- Previous TB treatment (possible acquired resistance) with ongoing risk factors (silicosis, HIV, mining exposure)

### Treatment Plan
1. **MDR-TB treatment (WHO shorter all-oral regimen, 9-11 months — eligible as fluoroquinolone-sensitive, no prior second-line drug exposure):**
   - Intensive phase (4-6 months): Bedaquiline 400 mg daily x 2 weeks then 200 mg 3x/week + Levofloxacin 750-1000 mg daily + Linezolid 600 mg daily + Ethionamide 500 mg daily + Clofazimine 100 mg daily + Pyrazinamide 1500 mg daily + Ethambutol 1200 mg daily
   - Continuation phase (5 months): Levofloxacin + Clofazimine + Pyrazinamide + Ethambutol
   - Intensive phase extended to 6 months if sputum culture positive at month 4
   - Monitor sputum cultures monthly until conversion, then at months 5, 8, and end of treatment
2. **Linezolid monitoring (most toxic drug in regimen):**
   - Monthly CBC (myelosuppression: anemia, thrombocytopenia, neutropenia)
   - Monthly visual acuity and color vision testing (optic neuritis — irreversible)
   - Peripheral neuropathy assessment at each visit
   - Pyridoxine (vitamin B6) 100 mg daily for neuropathy prevention
   - Reduce to 300 mg daily or discontinue if toxicity develops
3. **Bedaquiline monitoring:**
   - ECG at baseline, 2 weeks, monthly (QTc prolongation risk)
   - Hold if QTc > 500 ms; hepatic function monitoring monthly
4. **HIV management:**
   - Restart ART with adherence support 2 weeks after MDR-TB treatment initiation (delay reduces IRIS risk)
   - Switch to dolutegravir-based regimen with adherence assessment; if virological failure confirmed despite good adherence, perform genotypic resistance testing
   - Co-trimoxazole prophylaxis (CD4 < 200)
   - Monitor for immune reconstitution inflammatory syndrome (IRIS) — heightened risk with CD4 89
5. **Nutritional support:**
   - Nutritional assessment and supplementation (ready-to-use therapeutic food, RUTF)
   - Pyridoxine 100 mg daily, multivitamins, folate
   - Food support for the household (food insecurity drives non-adherence)
6. **Infection prevention and control:**
   - Patient to wear surgical mask when outside isolation
   - Household infection control: open windows, improve ventilation, reduce overcrowding
   - Sputum culture conversion documented before de-isolation

**PUBLIC HEALTH INTERVENTIONS:**
7. **Contact investigation (critical):**
   - Screen all 7 household contacts: symptom screening, chest X-ray, sputum collection for any symptomatic contacts
   - Children < 5 years (the 4-year-old): initiate preventive therapy (levofloxacin-based regimen for MDR-TB contacts) regardless of symptoms after excluding active TB
   - Mother (coughing for 1 month): urgent sputum testing with Xpert MTB/RIF Ultra
   - HIV testing for all household contacts
   - Mine coworker notification through occupational health services
8. **Cross-border coordination:**
   - Notify both Lesotho and South Africa national TB programs (cross-border referral)
   - Ensure treatment continuity if patient returns to South Africa through bilateral health agreements
9. **Adherence support:**
   - Video-observed therapy (VOT) or community health worker-supported DOT
   - Treatment supporter identified (wife)
   - Alcohol cessation counseling (alcohol increases hepatotoxicity risk and non-adherence)
   - Smoking cessation
   - Monthly multidisciplinary team review (clinician, nurse, social worker, counselor)
10. **Occupational health:**
    - Report to mining company occupational health department
    - Silicosis surveillance and worker compensation claim
    - Advocate for improved mine ventilation and dust suppression

### Key Learning Points
- Xpert MTB/RIF Ultra has transformed TB diagnosis by providing simultaneous detection of M. tuberculosis and rifampicin resistance within 2 hours at point of care; it should be the initial diagnostic test for all presumptive TB cases, especially in HIV-positive individuals and high-MDR-TB-burden settings
- The WHO shorter all-oral MDR-TB regimen (9-11 months with bedaquiline, linezolid, levofloxacin, clofazimine) has replaced injectable-based regimens and significantly improves outcomes and tolerability; eligibility depends on fluoroquinolone sensitivity and no prior second-line drug use
- TB-HIV co-management requires careful timing of ART initiation (2-8 weeks after TB treatment), monitoring for IRIS, and attention to drug-drug interactions; in severely immunocompromised patients (CD4 < 50), ART should start within 2 weeks
- Silicosis is the strongest occupational risk factor for TB (30-fold increased risk) and is endemic among gold miners in southern Africa; the silicosis-TB-HIV syndemic is a major public health challenge requiring intersectoral collaboration between health and mining sectors
- Contact investigation for MDR-TB must include MDR-TB-specific preventive therapy for close contacts, particularly children under 5; this is a critical and often neglected component of MDR-TB control programs

---

## Case 3: Maternal Mortality Reduction Program

### Patient Presentation
**Demographics:** 24-year-old female subsistence farmer, G4P3 at 38 weeks gestation, rural district in Sierra Leone

**Chief Complaint:** "Heavy bleeding after delivery at home."

**History of Present Illness:**
The patient delivered her fourth child at home 3 hours ago, attended by a traditional birth attendant (TBA). The delivery was spontaneous vaginal with the baby presenting headfirst. The placenta was delivered by the TBA using fundal pressure and cord traction. Approximately 30 minutes after placental delivery, the patient developed heavy vaginal bleeding that has been continuous and soaking through multiple cloths.

The TBA attempted to manage the bleeding with traditional remedies (herbal preparations applied vaginally) and abdominal massage for 2 hours before the family decided to bring the patient to the district health center. The journey from her village took 1 hour by motorcycle (the only available transport, as the village is 45 km from the nearest health facility with no paved road access).

The patient appears confused, pale, and is actively bleeding per vaginum on arrival. The TBA reports that the placenta appeared complete when delivered. The newborn is alive and was brought along, appearing healthy. The patient had no antenatal care during this pregnancy.

**Past Medical History:**
- G4P3 (three previous uncomplicated home deliveries)
- No prior cesarean sections
- Chronic anemia (never formally diagnosed or treated)
- No known HIV status
- Last delivery 14 months ago (short inter-pregnancy interval)

**Medications:**
- None
- No antenatal iron or folate supplementation
- No tetanus vaccination in this pregnancy

**Social History:**
- Subsistence farmer
- Married at age 16, first pregnancy at age 17
- No formal education
- Lives in remote village with no health facility
- Nearest comprehensive emergency obstetric care (CEmOC) facility: 120 km (referral hospital)
- Husband is the health decision-maker (delayed care-seeking)
- No mobile phone in household

**Family History:**
- Older sister: Died during childbirth at age 22 (hemorrhage reported)
- Mother: 8 pregnancies, 6 living children

### Physical Examination
- **Vital Signs:** BP 78/42 mmHg (severe hypotension), HR 138 bpm (tachycardia), RR 32, Temp 36.1°C (hypothermic), SpO2 88% on RA
- **General:** Profoundly pale, confused, restless, cold clammy extremities — clinical picture of hypovolemic shock (Class III-IV hemorrhage)
- **Estimated blood loss:** > 1500 mL (based on soaked cloths, ongoing active bleeding)
- **Abdomen:** Uterus palpable 2 cm above the umbilicus, soft and "boggy" (atonic), not well-contracted
- **Pelvic examination:** Active bright red bleeding per vaginum, cervical os dilated 2 cm, clots expressed with fundal massage, no obvious cervical or vaginal lacerations on initial examination (limited by setting)
- **Extremities:** Cold, mottled peripheries, capillary refill > 5 seconds
- **Neurological:** Confused, responding to voice but not fully oriented

### Workup and Results

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| Hemoglobin (HemoCue point-of-care) | 4.8 g/dL | 11-14 g/dL (pregnant) |
| Blood type and crossmatch | O positive | - |
| Malaria RDT | Positive (P. falciparum) | Negative |
| HIV rapid test | Negative | Negative |
| Urinalysis (dipstick) | Protein 2+, blood 3+ | Negative |
| Bedside clotting test (Lee-White) | Clot forms at 8 minutes, remains stable | Normal: clot forms < 10 min |

**Imaging/Additional Studies:**
- No ultrasound available at district health center
- No blood bank at district health center; 2 units of O-negative whole blood available from walking blood bank (pre-screened volunteer donors)
- Estimated blood loss based on clinical assessment: > 2000 mL (Class IV hemorrhage)

### Clinical Image

![Three delays model in maternal mortality](case_03_image.jpg)

*Diagram illustrating the Three Delays Model of maternal mortality: Delay 1 (decision to seek care) driven by cultural factors, gender dynamics, and lack of recognition of danger signs; Delay 2 (reaching care) driven by distance, transport, cost, and road infrastructure; Delay 3 (receiving adequate care) driven by facility capacity, skilled workforce, blood products, and referral systems. Applied to the case with specific intervention points identified. Source: Educational illustration.*

### Diagnosis
**Primary Postpartum Hemorrhage (PPH) due to Uterine Atony, Class IV Hypovolemic Shock, Severe Anemia (Hb 4.8 g/dL, pre-existing chronic anemia exacerbated by acute blood loss), Concurrent Plasmodium falciparum Malaria**

**Key Diagnostic Criteria:**
- Postpartum hemorrhage defined as blood loss > 500 mL after vaginal delivery; this patient has estimated loss > 2000 mL (severe PPH)
- Uterine atony confirmed by soft, boggy uterus above umbilicus that is not well-contracted
- Hypovolemic shock: tachycardia, hypotension, altered mental status, cold peripheries (Class IV hemorrhage = > 40% blood volume loss)
- Severe anemia (Hb 4.8) reflecting both acute hemorrhage and pre-existing chronic anemia (likely iron deficiency from multiparity, short inter-pregnancy interval, malaria, and no supplementation)
- Contributing factors to atony: grand multiparity, no active management of third stage of labor (AMTSL), prolonged manipulation by TBA

### Treatment Plan
**IMMEDIATE EMERGENCY MANAGEMENT (at district health center):**
1. **Simultaneous resuscitation and hemorrhage control (team approach):**
   - **Airway/Breathing:** High-flow oxygen, left lateral tilt
   - **IV access:** Two large-bore cannulae (16-18G), rapid crystalloid infusion (warmed Normal Saline or Ringer's Lactate 2 L bolus)
   - **Blood transfusion:** Transfuse 2 units whole blood (from walking blood bank) immediately; activate additional walking blood bank donors
   - **Tranexamic acid:** 1 g IV over 10 minutes (WOMAN trial: reduces death from bleeding by 31% if given within 3 hours of delivery; it is now recommended by WHO for all PPH)
   - **Keep warm:** Blankets, warm IV fluids (hypothermia worsens coagulopathy)
2. **Uterine atony management (stepwise approach):**
   - **Bimanual uterine massage:** Continuous until uterus contracts
   - **Uterotonics (all available agents simultaneously in severe PPH):**
     - Oxytocin 10 IU IM immediately + 40 IU in 1 L NS IV infusion (maximum 3 L oxytocin solution)
     - Misoprostol 800 mcg sublingual (if oxytocin insufficient or as adjunct in resource-limited setting; heat-stable, requires no refrigeration)
     - Ergometrine 0.2 mg IM (if available and no hypertension)
   - **Uterine balloon tamponade:** If uterotonics fail, insert condom catheter tamponade (Ellavi UBT or improvised: condom tied to Foley catheter, inflated with 300-500 mL saline) — this is a life-saving bridge-to-referral device
   - **Bimanual compression** if balloon not available
   - **Non-pneumatic anti-shock garment (NASG):** Apply immediately if available — compresses lower body, autotransfuses approximately 500 mL to vital organs, stabilizes for transport
3. **Concurrent malaria treatment:** Artemether-lumefantrine (postpartum, safe in breastfeeding)
4. **Referral for definitive care:**
   - If hemorrhage not controlled with above measures, immediate referral to CEmOC facility (120 km)
   - NASG and uterine balloon tamponade in situ during transport
   - IV fluids and blood running during transport
   - Call ahead to referral hospital to prepare for possible surgical intervention (B-Lynch suture, uterine artery ligation, or hysterectomy)
   - Arrange ambulance or fastest available transport

**PUBLIC HEALTH / PROGRAM INTERVENTIONS (Addressing the Three Delays):**
5. **Delay 1 (Decision to seek care):**
   - Community health worker (CHW) training program: educate communities on obstetric danger signs (bleeding, convulsions, fever, prolonged labor)
   - Birth preparedness and complication readiness (BPCR) plans: identify transport, save money, identify blood donor, identify decision-maker during pregnancy
   - Engage TBAs as community health promoters (recognize danger signs and facilitate referral) rather than delivery attendants
   - Address gender dynamics: involve men in antenatal education to enable timely decision-making
6. **Delay 2 (Reaching care):**
   - Maternity waiting homes near health facilities for women in final month of pregnancy
   - Community emergency transport schemes (motorcycle ambulances, community transport funds)
   - Mobile phone networks for emergency communication
   - Road infrastructure advocacy
7. **Delay 3 (Receiving care):**
   - EmOC signal function assessment at district health center: ensure 24/7 capacity for basic EmOC (parenteral uterotonics, parenteral antibiotics, parenteral anticonvulsants, manual removal of placenta, removal of retained products, assisted vaginal delivery, neonatal resuscitation)
   - Blood supply: establish and maintain walking blood bank with pre-screened community volunteer donors
   - Skills training: ALSO (Advanced Life Support in Obstetrics) or LSTM EmOC training for midwives and clinical officers
   - Supply chain: ensure constant availability of oxytocin (cold chain), misoprostol (heat-stable alternative), tranexamic acid, magnesium sulfate, UBT devices, NASG
   - Quality improvement: maternal death surveillance and response (MDSR) implementation

### Key Learning Points
- Postpartum hemorrhage is the leading cause of maternal mortality globally, responsible for 27% of maternal deaths, with the vast majority occurring in low- and middle-income countries; most deaths from PPH are preventable with active management of the third stage of labor (AMTSL), uterotonics, and timely access to emergency obstetric care
- Tranexamic acid (1 g IV within 3 hours of bleeding onset) reduces death from PPH by 31% (WOMAN trial, 20,000+ women); it is inexpensive, heat-stable, and should be available at every delivery facility — it is now a WHO Essential Medicine for PPH
- The condom catheter uterine balloon tamponade is a low-cost, life-saving intervention for uncontrolled PPH when surgical options are unavailable; it arrests hemorrhage in 80-90% of cases and serves as a critical bridge-to-referral in settings far from surgical care
- The Three Delays Model (delay in deciding to seek care, delay in reaching care, delay in receiving adequate care) provides the analytical framework for understanding and addressing maternal mortality; effective programs must target all three delays simultaneously
- Pre-existing anemia (from iron deficiency, malaria, and short inter-pregnancy intervals) dramatically reduces a woman's physiologic reserve to tolerate hemorrhage; a woman with hemoglobin of 7 g/dL who loses 1000 mL may die, while a woman with hemoglobin of 12 g/dL can survive the same loss — making antenatal anemia prevention a critical upstream intervention for hemorrhage mortality reduction